Transaction deepens healthcare offerings in medical device
solutions
WILMINGTON, Del., June 25,
2024 /PRNewswire/ -- DuPont (NYSE: DD) today
announced it has signed an agreement to acquire Donatelle Plastics
Incorporated, a leading medical device contract manufacturer
specializing in the design, development and manufacture of medical
components and devices. The transaction is expected to close in the
third quarter 2024, subject to satisfaction of customary closing
conditions and receipt of regulatory approvals.
"Our healthcare strategy is focused on offering a comprehensive
suite of solutions for customers in high-growth therapeutic areas,"
said Jon Kemp, President, DuPont
Electronics & Industrial (E&I). "Donatelle Plastics
Incorporated will be the second acquisition, following Spectrum
last year, that will deepen our expertise in the medical device
market segments and enhance our position as a partner of choice for
our customers."
DuPont's healthcare exposure within the Industrial Solutions
line of business of the E&I segment includes Spectrum, a leader
in medical device components, and Liveo™, a leader in silicone
solutions for healthcare applications. The acquisition of Donatelle
Plastics Incorporated will bring complementary advanced
technologies and capabilities including medical device injection
molding, liquid silicone rubber processing, precision machining,
device assembly, and tool building. Donatelle Plastics Incorporated
has a strong financial growth profile aligned to attractive
therapeutic areas including electrophysiology, drug delivery,
diagnostics, cardiac rhythm management, neurostimulation, and
orthopedic extremities.
Founded in 1967 and headquartered in New Brighton, Minnesota, Donatelle Plastics
Incorporated has a workforce of more than 400 employees and
operates a facility strategically located in a medical technologies
hub near leading original equipment manufacturers. Donatelle
Plastics Incorporated has established decades-long relationships by
providing best-in-class customer service, top-notch quality and
injection molding expertise. They are recognized for innovation in
medical device and component manufacturing, particularly in complex
applications where quality, reliability and technical expertise is
required for critical end-use applications.
"We're excited for this next chapter in Donatelle's journey and
for our team of highly talented and skilled employees to join
DuPont," said Treasa Springett,
President of Donatelle Plastics Incorporated. "As a part of a
broader healthcare offering, we will have even greater impact on
patient outcomes by enabling the innovation and development of next
generation devices for patients worldwide."
Advisors
Ballard Spahr LLP served
as legal advisor to DuPont. Piper Sandler
Companies served as financial advisor and Fredrikson
& Byron P.A. served as legal advisor
to Donatelle.
About DuPont
DuPont (NYSE: DD) is a global innovation
leader with technology-based materials and solutions that help
transform industries and everyday life. Our employees apply diverse
science and expertise to help customers advance their best ideas
and deliver essential innovations in key markets including
electronics, transportation, construction, water, healthcare and
worker safety. More information about the company, its businesses
and solutions can be found at www.dupont.com. Investors can access
information included on the Investor Relations section of the
website at investors.dupont.com.
Cautionary Statement about Forward-Looking
Statements
Overview: On May 22, 2024, DuPont
announced a plan to separate the company into three distinct,
publicly traded companies. Under the plan, DuPont would execute the
proposed separations of its Electronics and Water businesses in a
tax-free manner to its shareholders leaving DuPont to continue as a
diversified industrial company following completion of the
separations. DuPont expects to complete the separations
within 18 to 24 months of the announcement date. The separation
transactions will not require a shareholder vote and are subject to
satisfaction of customary conditions, including final approval by
DuPont's Board of Directors, receipt of tax opinion from counsel,
the filing and effectiveness of Form 10 registration statements
with the U.S. Securities and Exchange Commission, applicable
regulatory approvals and satisfactory completion of financing.
Please refer to the announcement and presentation materials from
May 22, 2024, posted to the Investor
section of www.dupont.com for more information.
Effective as of January 1, 2024,
Electronics & Industrial realigned certain product lines that
comprise its business units (Industrial Solutions, Interconnect
Solutions and Semiconductor Technologies) that are intended to
optimize business operations across the segment leading to enhanced
value for customers and cost savings. The Net Trade Revenue by
Segment and Business or Major Product Line has been recast for all
periods presented to reflect the new structure. The realignment did
not result in changes to total Electronics and Industrial segment
net sales.
On November 1, 2023, DuPont
completed the divestiture of the Delrin® acetal
homopolymer (H-POM) business to TJC LP, (the "Delrin®
Divestiture"). The results of operations for the three months ended
March 31, 2023, present the financial
results of the Delrin® Divestiture as discontinued
operations. Unless otherwise indicated, the discussion of results,
including the financial measures further discussed below, refers
only to DuPont's Continuing Operations and does not include
discussion of balances or activity of the Delrin®
Divestiture. This communication contains "forward-looking
statements" within the meaning of the federal securities laws,
including Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
In this context, forward-looking statements often address expected
future business and financial performance and financial condition,
and often contain words such as "expect," "anticipate," "intend,"
"plan," "believe," "seek," "see," "will," "would," "target,
"outlook," "stabilization," "confident," "preliminary," "initial,"
and similar expressions and variations or negatives of these words.
All statements, other than statements of historical fact, are
forward-looking statements, including statements regarding outlook,
expectations and guidance. Forward-looking statements address
matters that are, to varying degrees, uncertain and subject to
risks, uncertainties, and assumptions, many of which that are
beyond DuPont's control, that could cause actual results to differ
materially from those expressed in any forward-looking
statements.
Forward-looking statements are not guarantees of future results.
Some of the important factors that could cause DuPont's actual
results to differ materially from those projected in any such
forward-looking statements include, but are not limited to: (i) the
ability of DuPont to effect the separation transactions described
above and to meet the conditions related thereto; (ii) the
possibility that the separation transactions will not be completed
within the anticipated time period or at all; (iii) the possibility
that the separation transactions will not achieve their intended
benefits; (iv) the impact of the separation transactions on
DuPont's businesses and the risk that the separations may be more
difficult, time-consuming or costly than expected, including the
impact on DuPont's resources, systems, procedures and controls,
diversion of management's attention and the impact and possible
disruption of existing relationships with customers, suppliers,
employees and other business counterparties; (v) the possibility of
disruption, including disputes, litigation or unanticipated costs,
in connection with the separation transactions; (vi) the
uncertainty of the expected financial performance of DuPont or the
separated companies following completion of the separation
transactions; (vii) negative effects of the announcement or
pendency of the separation transactions on the market price of
DuPont's securities and/or on the financial performance of DuPont;
(viii) the ability to achieve anticipated capital structures in
connection with the separation transactions, including the future
availability of credit and factors that may affect such
availability; (ix) the ability to achieve anticipated credit
ratings in connection with the separation transactions; (x) the
ability to achieve anticipated tax treatments in connection with
the separation transactions and completed and future, if any,
divestitures, mergers, acquisitions and other portfolio changes and
the impact of changes in relevant tax and other laws; (xi) risks
and uncertainties related to the settlement agreement concerning
PFAS liabilities reached June 2023
with plaintiff water utilities by Chemours, Corteva, EIDP and
DuPont; (xii) risks and costs related to each of the parties
respective performance under and the impact of the arrangement to
share future eligible PFAS costs by and between DuPont, Corteva and
Chemours, including the outcome of any pending or future litigation
related to PFAS or PFOA, including personal injury claims and
natural resource damages claims; the extent and cost of ongoing
remediation obligations and potential future remediation
obligations; changes in laws and regulations applicable to PFAS
chemicals; (xiii) indemnification of certain legacy liabilities;
(xiv) the failure to realize expected benefits and effectively
manage and achieve anticipated synergies and operational
efficiencies in connection with the separation transactions and
completed and future, if any, divestitures, mergers, acquisitions,
and other portfolio management, productivity and infrastructure
actions; (xv) the risks and uncertainties, including increased
costs and the ability to obtain raw materials and meet customer
needs from, among other events, pandemics and responsive actions;
(xvi) timing and recovery from demand declines in consumer-facing
markets, including in China;
(xvii) adverse changes in worldwide economic, political,
regulatory, international trade, geopolitical, capital markets and
other external conditions; and other factors beyond DuPont's
control, including inflation, recession, military conflicts,
natural and other disasters or weather-related events, that impact
the operations of the company, its customers and/or its suppliers;
(xviii) the ability to offset increases in cost of inputs,
including raw materials, energy and logistics; (xix) the risks
associated with demand and market conditions in the semiconductor
industry and associated end markets, including from continuing or
expanding trade disputes or restrictions, including on exports to
China of U.S.-regulated products
and technology; (xx) the risks, including ability to achieve, and
costs associated with DuPont's sustainability strategy, including
the actual conduct of the company's activities and results thereof,
and the development, implementation, achievement or continuation of
any goal, program, policy or initiative discussed or expected;
(xxi) other risks to DuPont's business and operations, including
the risk of impairment; (xxii) the possibility that the Company may
fail to realize the anticipated benefits of the $1 billion share repurchase program announced on
February 6, 2024 and that the program
may be suspended, discontinued or not completed prior to its
termination on June 30, 2025;
and (xxiii) other risk factors discussed in DuPont's most recent
annual report and subsequent current and periodic reports filed
with the U.S. Securities and Exchange Commission. Unlisted factors
may present significant additional obstacles to the realization of
forward-looking statements. Consequences of material differences in
results as compared with those anticipated in the forward-looking
statements could include, among other things, business or supply
chain disruption, operational problems, financial loss, legal
liability to third parties and similar risks, any of which could
have a material adverse effect on DuPont's consolidated financial
condition, results of operations, credit rating or liquidity. You
should not place undue reliance on forward-looking statements,
which speak only as of the date they are made. DuPont assumes no
obligation to publicly provide revisions or updates to any
forward-looking statements whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by securities and other applicable
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dupont-to-acquire-donatelle-plastics-incorporated-302181153.html
SOURCE DuPont